Mukta Prasad

Mukta Prasad

Profile ID RP-000-2264 Joined 2023-01-18 2 articles
3
Total Views
2
Total Publications
3
Publication Views

Articles(2)

Authors: Shilpi Agarwal, Sugyani Satapathy, Mukta Prasad

DOI: 10.18231/j.ijooo.2021.059  

Volume7

Issue3

Pages289-293

Abstract

Aims: This prospective drug trial was done to compare latanoprost versus combination therapy of latanoprost and timolol maleate. Methods and Materials: Patient were screened for primary open angle glaucoma and grouped as per pharmacological drugs used and measured IOP baseline before initiation of study. Group I consisting all patients with latanoprost monotherapy and Group II consisting of patients already using either latanoprost or timolol. Further A,B & C was assigned as per IOP baseline. Results: In group I (Monotherapy), 28 patients were completed the follow up. The mean baseline IOP was 27.4 millimeter of Hg with standard deviation of 2.59. After 12 weeks of study, mean IOP was 19.66 millimeter of Hg with SD of 2.76. Mean IOP difference from baseline was 7.4 millimeter of Hg. So fall of 27.3% in IOP from pre-treatment level. In group II (Combination therapy), 19 patients were completed the follow up. The mean baseline IOP was 27.35 millimeter of Hg with standard deviation of 2.6. After 12 weeks of study mean IOP difference from baseline was 8.1 millimeter of Hg with SD of 2.0 millimeter of Hg i.e. a fall of 29.63% in IOP from pre-treatment level. Conclusions: Combination therapy fared slightly better that Latanoprost alone in overall pressure reduction.   Keywords: Prostaglandins, Glaucoma, Timolol, Beta adrenergic, Dual therapy

View Article

Authors: Abhishek Ranjan, Satapathy K Sugyani, Mukta Prasad

DOI: 10.18231/j.ijooo.2021.037  

Volume7

Issue2

Pages190-194

Abstract

Background: Glaucoma is progressive optical neuropathy which is challenging to treat despite advances in medical and interventional mode of treatments. Primary open angle glaucoma(POAG) is generally associated with diabetes mellitus and hypertension. Any ocular topical pharmacological agent which is to be used in POAG to maintain intraocular pressure have to be very efficacious with good safety profile. We conducted a study comparing travoprost with latanoprost and timolol as single therapeutic agent having favorable outcome. Materials and Methods: Seventy five patients were included in the study for a period of two years. After ethical clearance, patients were randomly allocated to three groups of treatment arm having 25 patients in each group. IOP was noted at 8 A.M, 10 A.M, 4 P.M on two eligibility visits for the same eye. Data collected included demographic data, blood pressure, visual acuity, ocular hyperaemia, Slit lamp finding, IOP & fundus examination. Result: Travoprost treated patients had minimum IOP significantly lower at all visits than those using timolol (p Conclusion: TRAVOPROST 0.004% once daily or in combination with other agents is the most effective and safest topical agents for patients of primary open angle glaucoma with the best safety profile.   Keywords: (MeSH)­ prostaglandin analogue, IOP, Ocular hyperaemia, Diurnal variations.

View Article

No matching articles

Try another word from the title, author or DOI.